RxDoctor Payments Data

Bilal Rayes, MD

Hospitalist · Upland, CANPI 1619095841

Payments from drug & device makers

$1,528in general payments, 2019–2025

Across 91 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$299
  • Johnson & Johnson$216
  • Scpharmaceuticals Inc.$190
  • Pfizer$167
  • Merck$149
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$85
  • plus $422 from 10 others

What the payments were for

  • Food & beverage$1,50799%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,528 in reported general payments places this provider in the 90th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$206,624
Medicare patients
136
Services billed
1,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$85,213
XifaxanRifaximin40$61,420
BrilintaTicagrelor33$17,275
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,465
EntrestoSacubitril/Valsartan30$9,320
ErtapenemErtapenem Sodium19$6,536
JanuviaSitagliptin Phosphate25$6,298
MovantikNaloxegol Oxalate25$5,649
Sucralfate54$5,015
ProtonixPantoprazole Sodium11$4,675
XareltoRivaroxaban13$4,356
Midodrine Hcl38$3,731
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$2,108
Atorvastatin Calcium153$2,016
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate86$1,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Protonix$167$89,888226 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$85$61,42040 claims
AstraZenecaBrilinta$85$17,27533 claims
NovartisEntresto$299$9,32030 claims
MerckJanuvia$149$6,29825 claims
Johnson & JohnsonXarelto$216$4,35613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →